既往SARS-CoV-2感染对mRNA SARS-CoV-2疫苗接种后住院发生率及不良事件的影响:一项全国性回顾性队列研究
该全国性多中心回顾性队列研究纳入2020年12月11日至2021年8月31日在退伍军人健康管理局接种mRNA疫苗的退伍军人,比较接种前后每日住院、死亡及预设不良事件发生率,并按有无微生物学确诊SARS-CoV-2感染史分层。结果显示无既往感染史者第二剂前后住院率无变化,而有既往感染史者接种后住院率短暂升高后恢复基线,绝对风险约1:1000,作者认为两剂mRNA疫苗方案安全并支持进一步研究该人群最佳接种方案。
要点
- 无既往SARS-CoV-2感染史者第二剂接种后住院率与接种前无显著变化。
- 有既往感染史者第二剂接种后住院率短暂升高后恢复基线,绝对风险约1:1000。
- 作者认为两剂mRNA疫苗方案在合并症多的人群中安全,并支持进一步研究该人群最佳接种方案。
核心结论
- 两剂mRNA疫苗方案在合并症多的人群中是安全的。
- 有既往SARS-CoV-2感染史者接种后住院风险短暂升高,绝对风险约1:1000。
- 研究结果支持进一步研究该人群的最佳接种方案。
研究设计与样本
- 全国性多中心回顾性队列研究,纳入2020年12月11日至2021年8月31日在退伍军人健康管理局接种mRNA疫苗的退伍军人。
- 共3,118,802例接种第一剂,2,979,326例接种第二剂,其中102,829例有SARS-CoV-2感染史。
- 比较接种前后每日发生率,并按有无微生物学确诊SARS-CoV-2感染史分层。
主要发现
- 无既往感染史者第二剂接种后每日住院发生率为28.8/100,000,接种前为28.6/100,000,p=0.92。
- 有既往感染史者第二剂接种后每日住院发生率为158.2/100,000,接种前为57.3/100,000,p<0.001。
- 病历审查显示疫苗副作用(如发热、全身症状、乏力或跌倒)是住院的确定原因(39%)或可能原因(18%)。
- 受影响患者平均年龄75岁,90%至少有一种严重合并症,住院时间短(中位2天),健康迅速恢复基线。
- 有既往感染史者基线健康状况较差,无法就死亡风险得出结论。
临床怎么用
- 原文未据此给出推荐。
局限性
- 有既往感染史者基线健康状况较差,无法就死亡风险得出结论。
- 作者指出研究结果支持进一步研究该人群的最佳接种方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies evaluated the SARS-CoV-2 vaccine safety or compared adverse events following vaccination to those from infection. Limited data about the impact of prior infection on post-vaccine adverse events are available. The objective of this study was to evaluate the impact of prior SARS-CoV-2 infection on outcomes shortly after vaccination using a longitudinal design. METHODS: Nationwide, multicenter, retrospective cohort study of hospitalization, death, and pre-specified adverse event rates among Veterans who received mRNA vaccines within the Veterans Health Administration between 12/11/2020 and 8/31/2021. Daily incidence rates were compared before and after vaccine doses, stratified by history of microbiologically-confirmed SARS-CoV-2. RESULTS: 3,118,802 patients received a first dose and 2,979,326 a second, including 102,829 with a history of SARS-CoV-2 infection. Daily incident hospitalization rates were unchanged before and after the second dose among patients without previous infection (28.8/100,000 post-dose versus 28.6/100,000 pre-dose, p = 0.92). In previously-infected patients, the hospitalization rate increased above baseline one day following vaccination (158.2/100,000 after dose 2 versus 57.3/100,000 pre-dose, p < 0.001), then returned to baseline. Chart review indicated vaccine side effects, such as fever, constitutional symptoms, weakness, or falls, as the definite (39%) or possible (18%) cause of hospitalization. Affected patients had mean age 75, and 90% had at least one serious comorbidity. Hospitalizations were brief (median 2 days), with rapid return to baseline health. Worse baseline health among previously-infected patients prevented conclusions about mortality risk. CONCLUSIONS: Two-dose mRNA vaccine regimens are safe in a population with many comorbidities. Transient increased risks of hospitalization were identified among patients with prior SARS-CoV-2, absolute risk ∼1:1000. Findings support additional study regarding the optimal dosing schedule in this population. FUNDING: None.
引用
- Li LL, Zheng C, La J, et al. Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. Vaccine. 2022. PMID: 35078665. doi:10.1016/j.vaccine.2022.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。